The director purchases are a modest vote of confidence following a strong earnings beat, but the dollar amount is too small to be a meaningful signal for a $147B company. Monitor for any additional insider buying at higher volumes or C-suite participation to confirm conviction. The earnings beat and raised guidance are the more material catalysts for the stock.
Price Chart
Executive Summary
Two Pfizer directors, Ronald Blaylock and Mortimer Buckley, made open-market purchases totaling ~$1.96M on August 5, 2026, two days after the company reported a Q2 2026 adjusted EPS beat of $0.77 (+12.9% vs consensus) and raised full-year revenue guidance. The CEO's grant of 24 shares is a routine non-cash award. While the director purchases are a modest positive signal, the total dollar value is only ~0.001% of Pfizer's $147B market cap, making it trivial in scale and unlikely to move the stock. Historical calibration on PFE shows a 13% win rate at T+20 for prior reports, suggesting limited predictive power for this ticker.
Key Financial Metrics
Key Facts
- Two directors purchased ~$1.96M in open-market stock on August 5, 2026, at ~$25.50/share.
- Purchases occurred two days after Pfizer reported Q2 2026 adjusted EPS of $0.77 (12.9% beat) and raised FY2026 revenue guidance by $500M.
- Total insider purchases represent ~0.001% of Pfizer's $147.1B market cap — trivial in scale.
- CEO Albert Bourla received a non-cash grant of 24 shares worth $600 — no economic signal.
- Historical PFE reports show a 13% win rate at T+20, indicating low predictive value for insider activity at this ticker.
Financial Impact
~$1.96M in director open-market purchases, representing ~0.001% of market cap
Risk Factors
- Director purchases are small relative to market cap and may be routine portfolio adjustments, not conviction buys.
- Historical PFE insider activity has shown poor predictive power (13% win rate at T+20).
- GAAP net loss of $0.04/share due to $4.3B impairments tempers the adjusted EPS beat narrative.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-PFE-1786003622984 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 13, 2026 7w ago | Court Ruling | $26.80 $27.72 | ▲ +3.43% | ▲ +5.18% | $27.55 (+2.78%) |
Aug 12, 2026 7w ago | Insider Buy | $26.80 $27.72 | ▲ +3.43% | ▲ +5.18% | $27.55 (+2.78%) |
Aug 12, 2026 7w ago | Insider Cluster | $26.80 $27.72 | ▲ +3.43% | ▲ +5.18% | $27.55 (+2.78%) |
Aug 6, 2026 8w ago | Insider Cluster | $26.20 $28.81 | ▲ +9.95% | ▲ +9.35% | $27.55 (+5.13%) |
Aug 5, 2026 8w ago | Insider Cluster | $26.20 $28.81 | ▲ +9.95% | ▲ +9.35% | $27.55 (+5.13%) |
Aug 4, 2026 8w ago | 8-K | $25.41 $28.55 | ▲ +12.36% | ▲ +13.60% | $27.55 (+8.40%) |
Jul 31, 2026 9w ago | Court Ruling | $25.01 $27.96 | ▼ −11.80% | ▼ −8.81% | $27.55 (−10.14%) |
Jul 24, 2026 10w ago | Court Ruling | $24.54 $28.07 | ▲ +14.38% | ▲ +10.76% | $27.55 (+12.25%) |
Jul 6, 2026 12w ago | ANALYST-DOWNGRADE | $23.72 $25.01 | ▼ −5.44% | ▼ −6.00% | $27.55 (−16.13%) |
Jun 18, 2026 15w ago | 8-K | $25.21 $25.14 | ▼ −0.28% | ▼ −0.81% | $27.55 (+9.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access